| Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries T Zelei, MJ Molnár, M Szegedi, Z Kaló Orphanet journal of rare diseases 11, 1-11, 2016 | 73 | 2016 |
| Epidemiology of Sanfilippo syndrome: results of a systematic literature review T Zelei, K Csetneki, Z Voko, C Siffel Orphanet journal of rare diseases 13, 1-11, 2018 | 65 | 2018 |
| Systematic literature review and meta-analysis on the epidemiology of methylmalonic acidemia (MMA) with a focus on MMA caused by methylmalonyl-CoA mutase (mut) deficiency T Almási, LT Guey, C Lukacs, K Csetneki, Z Vokó, T Zelei Orphanet journal of rare diseases 14 (1), 84, 2019 | 48 | 2019 |
| The European challenges of funding orphan medicinal products M Szegedi, T Zelei, F Arickx, A Bucsics, E Cohn-Zanchetta, J Fürst, ... Orphanet journal of rare diseases 13, 1-8, 2018 | 41 | 2018 |
| Guidance for the harmonisation and improvement of economic evaluations of personalised medicine H Vellekoop, S Huygens, M Versteegh, L Szilberhorn, T Zelei, B Nagy, ... Pharmacoeconomics 39 (7), 771-788, 2021 | 32 | 2021 |
| Financing and reimbursement models for personalised medicine: a systematic review to identify current models and future options R Koleva-Kolarova, J Buchanan, H Vellekoop, S Huygens, M Versteegh, ... Applied Health Economics and Health Policy 20 (4), 501-524, 2022 | 25 | 2022 |
| Systematic literature review and meta-analysis on the epidemiology of propionic acidemia T Almási, LT Guey, C Lukacs, K Csetneki, Z Vokó, T Zelei Orphanet journal of rare diseases 14 (1), 40, 2019 | 25 | 2019 |
| The net benefit of personalized medicine: a systematic literature review and regression analysis H Vellekoop, M Versteegh, S Huygens, IC Ramos, L Szilberhorn, T Zelei, ... Value in Health 25 (8), 1428-1438, 2022 | 20 | 2022 |
| Criteria and scoring functions used in multi-criteria decision analysis and value frameworks for the assessment of rare disease therapies: a systematic literature review T Zelei, ND Mendola, B Elezbawy, B Németh, JD Campbell PharmacoEconomics-open 5 (4), 605-612, 2021 | 15 | 2021 |
| Policy objective of generic medicines from the investment perspective: the case of clopidogrel P Elek, A Harsányi, T Zelei, Z Kaló Health Policy 121 (5), 558-565, 2017 | 14 | 2017 |
| Cost-effectiveness analysis of treating patients with NTRK-positive cancer with the histology-independent therapy entrectinib S Huygens, H Vellekoop, M Versteegh, I Santi, L Szilberhorn, T Zelei, ... Value in Health 26 (2), 193-203, 2023 | 10 | 2023 |
| Association between transplant glomerulopathy and graft outcomes following kidney transplantation: a meta-analysis G Kovács, G Devercelli, T Zelei, I Hirji, Z Vokó, PA Keown PLoS One 15 (4), e0231646, 2020 | 10 | 2020 |
| Comparison of efficacy and local tolerability of estradiol metered-dose transdermal spray to estradiol patch in a network meta-analysis G Kovács, T Zelei, Z Vokó Climacteric 19 (5), 488-495, 2016 | 5 | 2016 |
| Cost–effectiveness of extended DPYD testing before fluoropyrimidine chemotherapy in metastatic breast cancer in the UK R Koleva-Kolarova, H Vellekoop, S Huygens, M Versteegh, MR Mölken, ... Personalized Medicine 20 (4), 339-355, 2023 | 4 | 2023 |
| Beyond medicines’ barriers: Exploring the true cost of multiple myeloma M Choon-Quinones, T Zelei, M Barnett, P Keown, B Durie, Z Kaló, ... Journal of Medical Economics 25 (1), 1167-1175, 2022 | 4 | 2022 |
| Systematic literature review of health economic models developed for multiple myeloma to support future analyses M Choon-Quinones, T Zelei, B Németh, M Tóth, XY Jia, M Barnett, ... Journal of Medical Economics 26 (1), 110-119, 2023 | 2 | 2023 |
| Financial incentives to promote personalized medicine in Europe: an overview and guidance for implementation R Koleva-Kolarova, L Szilberhorn, T Zelei, H Vellekoop, B Nagy, ... Personalized Medicine 20 (4), 305-319, 2023 | 2 | 2023 |
| Budget impact and transferability of cost–effectiveness of DPYD testing in metastatic breast cancer in three health systems R Koleva-Kolarova, H Vellekoop, S Huygens, M Versteegh, MR Mölken, ... Personalized Medicine 20 (4), 357-374, 2023 | 2 | 2023 |
| Patient and caregiver experience decision factors in treatment decision making: results of a systematic literature review of multiple myeloma decision aids M Choon-Quinones, D Hose, Z Kaló, T Zelei, JL Harousseau, B Durie, ... Value in Health 26 (1), 39-49, 2023 | 2 | 2023 |
| Lessons learned from the application of the HEcoPerMed guidance to three modeling case studies B Nagy, T Zelei, H Vellekoop, S Huygens, M Versteegh, MR Mölken, ... Personalized Medicine 20 (4), 401-411, 2023 | 1 | 2023 |
